Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for Eli Lilly & Co�
-0.97 (-1.16%)
Real-time:   10:14AM EST
NYSE real-time data - Disclaimer
Currency in USD
Range 82.68 - 84.03
52 week 67.60 - 92.85
Open 83.76
Vol / Avg. 361,383.00/4.55M
Mkt cap 91.60B
P/E 37.33
Div/yield 0.50/2.42
EPS 2.22
Shares 1.11B
Beta 0.16
Inst. own 77%
Jan 28, 2016
Q4 2015 Eli Lilly and Co Earnings Release - 9:30AM EST - Add to calendar
Jan 28, 2016
Q4 2015 Eli Lilly and Co Earnings Call - 9:00AM EST - Add to calendar
Jan 5, 2016
Eli Lilly and Co 2016 Financial Guidance Conference Call - 9:00AM EST - Add to calendar
Dec 8, 2015
Eli Lilly and Co Animal Health and Alzheimer's Disease Review - 9:00AM EST - Add to calendar
Nov 11, 2015
Eli Lilly and Co and Incyte Corp Webcast to Discuss Baricitinib Phase 3 Data - Webcast
Nov 10, 2015
Eli Lilly and Co at Credit Suisse Healthcare Conference
Nov 2, 2015
Eli Lilly and Co at �EBD BIO Europe- Fall
Oct 22, 2015
Q3 2015 Eli Lilly and Co Earnings Release
Oct 22, 2015
Q3 2015 Eli Lilly and Co Earnings Call
Sep 24, 2015
Eli Lilly and Co to Discuss EMPA-REG OUTCOME� Data Conference Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 16.12% 12.19%
Operating margin 19.38% 13.56%
EBITD margin - 24.00%
Return on average assets 8.87% 6.60%
Return on average equity 21.46% 14.49%
Employees 39,135 -
CDP Score - 85 B


Lilly Corporate Ctr
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company's products are sold in approximately 120 countries. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 50
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 55
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 61
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 46
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 49
Bio & Compensation  - Reuters
Darren J. Carroll Senior Vice President - Corporate Business Development
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 48
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 50
Bio & Compensation  - Reuters